Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

ABSTRACT:

Importance

BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established.

Objective

To investigate the relationship between BRAF V600E mutation and PTC-related mortality.

Design, setting, and participants

Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile range, 34-58 years) and an overall median follow-up time of 33 months (interquartile range, 13-67 months) after initial treatment at 13 centers in 7 countries between 1978 and 2011.

Main outcomes and measures

Patient deaths specifically caused by PTC.

Results

Overall, mortality was 5.3% (45/845; 95% CI, 3.9%-7.1%) vs 1.1% (11/1004; 95% CI, 0.5%-2.0%) (P < .001) in BRAF V

SUBMITTER: Xing M 

PROVIDER: S-EPMC3791140 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature